Oncology

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.

Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.

The drive for personalized approaches to cancer have helped to create treatments for patients with rare cancers who have few, if any, options.

Idecabtagene vicleucel prolonged progression-free survival by more than 1 year in a difficult-to-treat patient population with relapsed or refractory multiple myeloma.

HER2-low disease demands a different approach from that of HER2-negative disease.

The patient's list of medications reveals significant drug interactions to be addressed.

Trial meets its primary endpoint of progression-free survival regardless of mismatch repair status in patients with stage 3 or 4 or recurrent endometrial carcinoma.

By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in reduced bone loss.

Earlier this week, the FDA Oncologic Drugs Advisory Committee also voted 8 to 5 in support of data for dostarlimab-gxly in rectal cancer.

PARP inhibitors in particular have changed the therapeutic landscape for EOC.

Several studies have noted a potential link between methotrexate and an increased risk of skin cancer.

Numerous clinical trials are investigating the next generation of PARPi.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.

Investigators hope that new findings can cultivate new methods of facilitating immune response to attack lung tumors.

In a fact sheet released by the White House, President Joseph Biden called a $35 monthly cap on insulin for all Americans a “commonsense, life-saving protection.”

Approval of a novel antibody-drug conjugate ushers in new second-line option.

These agents are likely to become the mainstay of cancer treatment in the very near future.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.

Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.

Sacituzumab govitecan-hziy (Trodelvy) is a conjugated Trop-2-directed antibody and topoisomerase inhibitor previously approved for patients with triple-negative breast cancer.

Artificial intelligence technology is integrated into the services and products we use every day in our personal and professional lives.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Change is upon us, and opportunities for advancing treatment opportunities for patients continue to look strong.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.